Infectious Diseases Institute, Kampala, Uganda.
JMIR Res Protoc. 2024 Nov 15;13:e58140. doi: 10.2196/58140.
Antimicrobial resistance (AMR) is a major global public health concern, particularly in low- and middle-income countries where resources and infrastructure for an adequate response are limited. The World Health Organization (WHO) Global Antimicrobial Resistance Surveillance System (GLASS) was introduced in 2016 to address these challenges, outlining recommendations for priority pathogen-antibiotic combinations. Despite this initiative, implementation in Africa remains understudied. This scoping review aims to assess the current state of implementing WHO GLASS recommendations on antimicrobial sensitivity testing (AST) in Africa.
The primary objective of this study is to determine the current state of implementing the WHO GLASS recommendations on AST for priority pathogen-antimicrobial combinations. The review will further document if the reporting of AST results is according to "susceptible," "intermediate," and "resistant" recommendations according to GLASS.
Following the methodological framework by Arksey and O'Malley, studies published between January 2016 and November 2023 will be included. Search strategies will target electronic databases, including MEDLINE, Scopus, CINAHL, and Embase. Eligible studies will document isolates tested for antimicrobial sensitivity, focusing on WHO-priority specimens and pathogens. Data extraction will focus on key study characteristics, study context, population, and adherence to WHO GLASS recommendations on AST. Descriptive statistics involving summarizing the quantitative data extracted through measures of central tendency and variation will be used. Covidence and Microsoft Excel software will be used. This study will systematically identify, collate, and analyze relevant studies and data sources based on clear inclusion criteria to provide a clear picture of the progress achieved in the implementation of the WHO GLASS recommendations. Areas for further improvement will be documented to inform future efforts to strengthen GLASS implementation for enhanced AMR surveillance in Africa.
The study results are expected in August 2024.
To our knowledge, this scoping review will be the first to comprehensively examine the implementation of WHO GLASS recommendations in Africa, shedding light on the challenges and successes of AMR surveillance in the region. Addressing these issues aims to contribute to global efforts to combat AMR.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/58140.
抗菌药物耐药性（AMR）是一个主要的全球公共卫生关注点，特别是在资源和基础设施有限的低收入和中等收入国家。世界卫生组织（WHO）全球抗菌药物耐药性监测系统（GLASS）于 2016 年推出，以应对这些挑战，为优先病原体-抗生素组合提出了建议。尽管有了这一举措，但非洲的实施情况仍研究不足。本范围审查旨在评估在非洲实施世界卫生组织 GLASS 关于抗菌药物敏感性测试（AST）建议的现状。
本研究的主要目的是确定在非洲实施世界卫生组织 GLASS 关于优先病原体-抗生素组合 AST 建议的现状。审查还将记录 AST 结果的报告是否符合 GLASS 建议的“敏感”、“中介”和“耐药”。
遵循 Arksey 和 O'Malley 的方法框架，纳入 2016 年 1 月至 2023 年 11 月期间发表的研究。搜索策略将针对电子数据库，包括 MEDLINE、Scopus、CINAHL 和 Embase。合格的研究将记录用于抗菌药物敏感性测试的分离株，重点是世界卫生组织优先标本和病原体。数据提取将侧重于关键研究特征、研究背景、人群以及对世界卫生组织 GLASS 关于 AST 的建议的遵守情况。将使用描述性统计方法，通过集中趋势和变异的度量来总结提取的定量数据。将使用 Covidence 和 Microsoft Excel 软件。本研究将根据明确的纳入标准系统地识别、整理和分析相关研究和数据源，以清楚地了解在实施世界卫生组织 GLASS 建议方面取得的进展。将记录进一步改进的领域，以为加强非洲 GLASS 实施以加强抗菌药物耐药性监测提供信息。
预计研究结果将于 2024 年 8 月公布。
据我们所知，这是首次全面审查世界卫生组织 GLASS 建议在非洲的实施情况，揭示了该地区抗菌药物耐药性监测的挑战和成功。解决这些问题旨在为全球对抗抗菌药物耐药性的努力做出贡献。
国际注册报告标识符（IRRID）：PRR1-10.2196/58140.
